Graham Casey


Affiliation: Cleveland Clinic Foundation
Country: USA


  1. Casey G, Lindor N, Papadopoulos N, Thibodeau S, Moskow J, Steelman S, et al. Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer. JAMA. 2005;293:799-809 pubmed
    ..Conversion analysis substantially increases the diagnostic yield of genetic testing for mismatch repair mutations in patients diagnosed as having colorectal cancer. ..
  2. Hashimoto Y, Skacel M, Lavery I, Mukherjee A, Casey G, Adams J. Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer. 2006;6:241 pubmed
    ..Fascin may have prognostic value as an early biomarker for more aggressive colorectal adenocarcinomas. ..
  3. Casey G, Neville P, Plummer S, Xiang Y, Krumroy L, Klein E, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet. 2002;32:581-3 pubmed
    ..Men that are heterozygous with respect to the mutated allele have 50% greater risk of prostate cancer than non-carriers, and homozygotes have more than double the risk. ..
  4. Casey G, Neville P, Liu X, Plummer S, Cicek M, Krumroy L, et al. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet. 2006;15:735-41 pubmed
    ..48, 95%CI=1.02-2.14, P=0.04). These results implicate PODXL as a candidate prostate cancer tumor aggressiveness gene mapping to chromosome 7q32-q33. ..